MARTINSRIED, GERMANY and MUNICH, GERMANY--(Marketwire - February 07, 2011) -
MorphoSys AG /
MorphoSys Strengthens Patent Position on Lead Program MOR103
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
US Patent and Trademark Office (USPTO) has granted a patent
Company's most advanced proprietary compound MOR103. The new patent
7,867,495) covers MorphoSys's HuCAL antibody against GM-CSF as
pharmaceutical compositions comprising the same, and has a scheduled expiry
in 2026, not including any potential extensions.
This newly issued patent complements a US patent granted in 2008
medical uses of antibodies against GM-CSF, to which MorphoSys has
access under a license agreement with the University of Melbourne.
two patent families provide strong intellectual property protection
"The protection of our intellectual property is a central part of
business model," commented Dr. Simon Moroney, Chief Executive
MorphoSys AG. "We will continue to strengthen still further our
property position in antibody-based products and services, particularly
most important markets Europe, the USA and Asia."
Human GM-CSF (Granulocyte macrophage-colony stimulating factor), the
molecule of MorphoSys's lead program MOR103, is implicated in a
inflammatory and other conditions including rheumatoid arthritis
multiple sclerosis (MS). The HuCAL-derived, fully human antibody is
being tested in a clinical Phase 1b/2a trial in RA patients.
MorphoSys plans to start a Phase 1b safety study of MOR103 in multiple
patients in 2011.
Currently, the Company is prosecuting more than 40 different proprietary
families world-wide, in addition to those being pursued in cooperation
MorphoSys is an independent biotechnology company that develops novel
for therapeutic, diagnostic and research applications. The Company's
technology is one of the most powerful methods available for generating
human antibodies. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of
antibodies, one of the fastest-growing drug classes in human health-
Through its alliances with some of the world's leading pharmaceutical
MorphoSys has created a pipeline of more than 60 drug candidates. The
expanding its drug pipeline by adding new partnered programs, and by
portfolio of fully-owned therapeutic antibodies. For its proprietary
the Company is focused on the areas of oncology and inflammation. Its
advanced program MOR103, a first-in-class, fully human antibody against
is currently being tested in a Phase Ib/IIa trial in rheumatoid
patients. Via its business unit AbD Serotec, MorphoSys is expanding the
its technologies in the diagnostics and research markets.
headquartered in Munich, Germany and listed on the Frankfurt Stock
under the symbol "MOR". For further information, visit
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®
and RapMAT® are
registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Lena-Christ-Str. 48 Martinsried / München Germany
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE